Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Introduction β-synuclein is an emerging blood biomarker to study synaptic degeneration in Alzheimer´s disease (AD), but its relation to amyloid-β (Αβ) pathology is unclear. Methods We investigated the association of plasma β-synuclein levels with [18F] flutemetamol positron emission tomography (PET) in patients with AD dementia (n = 51), mild cognitive impairment (MCI-Aβ+ n = 18, MCI- Aβ- n = 30), non-AD dementias (n = 22), and non-demented controls (n = 5). Results Plasma β-synuclein levels were higher in Aβ+ (AD dementia, MCI-Aβ+) than in Aβ- subjects (non-AD dementias, MCI-Aβ-) with good discrimination of Aβ+ from Aβ- subjects and prediction of Aβ status in MCI individuals. A positive correlation between plasma β-synuclein and Aβ PET was observed in multiple cortical regions across all lobes. Discussion Plasma β-synuclein demonstrated discriminative properties for Aβ PET positive and negative subjects. Our data underline that β-synuclein is not a direct marker of Aβ pathology and suggest different longitudinal dynamics of synaptic degeneration versus amyloid deposition across the AD continuum. Highlights Blood and CSF β-synuclein levels are higher in Aβ+ than in Aβ- subjects. Blood β-synuclein level correlates with amyloid PET positivity in multiple regions. Blood β-synuclein predicts Aβ status in MCI individuals.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 51 participants. Blood β-synuclein levels were higher in people with amyloid PET positivity and could predict amyloid status in those with mild cognitive impairment. Its stated limit: The comparison groups were small (as few as 5 healthy controls), and this was a single memory-clinic cohort, so the findings need confirmation in larger, more diverse samples before the test could be used clinically.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Oeckl, P., Bluma, M., Bucci, M., Halbgebauer, S., Chiotis, K., Sandebring-Matton, A., et al. (2023). Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13046

Vancouver

Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13046. PMID: 37052206.

BibTeX

@article{oeckl2023-37052206,
  author  = {Oeckl, P. and Bluma, M. and Bucci, M. and Halbgebauer, S. and Chiotis, K. and Sandebring-Matton, A. and Ashton, N. J. and Molfetta, G. D. and others},
  title   = {{Blood β-synuclein is related to amyloid PET positivity in memory clinic patients}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.13046},
  pmid    = {37052206},
  url     = {https://doi.org/10.1002/alz.13046}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Blood β-synuclein levels were higher in people with amyloid PET positivity and could predict amyloid status in those with mild cognitive impairment. The authors state β-synuclein is not a direct marker of amyloid pathology, so it reflects synaptic degeneration rather than the amyloid deposits themselves.

Study details

Limitations

The comparison groups were small (as few as 5 healthy controls), and this was a single memory-clinic cohort, so the findings need confirmation in larger, more diverse samples before the test could be used clinically.

How this study scored 59/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 1 / 4 51 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 20 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.0 citations a year over 5 year(s) since 2023
Impact for its field and year 3 / 6 Cited 3.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Markus Otto: h-index 95 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37052206)
Free to read 0 / 2 Behind a paywall — scores zero
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →